Anzeige
Mehr »
Sonntag, 07.09.2025 - Börsentäglich über 12.000 News
Tokenisierung entfesselt: Republic führt die Ethereum-Revolution
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C2EY | ISIN: US04635X1028 | Ticker-Symbol: 2090
Tradegate
04.09.25 | 17:00
5,800 Euro
-10,08 % -0,650
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
ASTRIA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ASTRIA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
6,2506,55005.09.

Aktuelle News zur ASTRIA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiAstria Therapeutics to present STAR-0310 phase 1a data at EADV congress5
MiAstria Therapeutics, Inc.: Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025193Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial...
► Artikel lesen
13.08.Astria Therapeutics stock price target raised to $26 by JMP on HAE program progress19
13.08.Fortschritte bei HAE-Programm: JMP hebt Kursziel für Astria Therapeutics auf 26 US-Dollar an18
12.08.Astria TherapeuticS GAAP EPS of -$0.57 beats by $0.023
12.08.Astria Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans2
07.08.Astria Therapeutics licenses navenibart rights to Kaken for HAE6
06.08.Astria Therapeutics Licenses Japan Rights To Navenibart In $16 Mln Deal6
ASTRIA THERAPEUTICS Aktie jetzt für 0€ handeln
06.08.Astria Therapeutics, Inc. - 8-K, Current Report3
13.06.Astria Therapeutics, Inc.: Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress448-- Q3M Arm Demonstrated 95% Mean Monthly Attack-Rate Reduction -- -- Q6M Arm Demonstrated 86% Mean Monthly Attack-Rate Reduction - -- Well-Tolerated with a Favorable Safety Profile -- --...
► Artikel lesen
06.06.Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress377Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four...
► Artikel lesen
04.06.Astria Therapeutics bei Jefferies-Konferenz: Strategische Pipeline-Einblicke22
29.05.Citizens JMP hält an Kursziel von 25 US-Dollar für Astria Therapeutics-Aktie fest36
29.05.Citizens JMP maintains $25 target on Astria Therapeutics stock8
23.05.Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop367Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at...
► Artikel lesen
14.05.JMP cuts Astria Therapeutics target to $25, maintains rating9
13.05.Astria TherapeuticS GAAP EPS of -$0.58 misses by $0.108
13.05.Astria Therapeutics, Inc. - 10-Q, Quarterly Report6
01.05.Astria Therapeutics meldet Fortschritte bei HAE-Medikamentenstudie22
01.05.Astria Therapeutics reports progress in HAE drug trial3
Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1